24-Month Efficacy of Viscodilation of Schlemm’s Canal and the Distal Outflow System with iTrack Ab-Interno Canaloplasty for the Treatment of Primary Open-Angle Glaucoma

Figures & data

Table 1 Preoperative Patient Demographics and Characteristics for All Eyes

	Preoperative Demographics
		n	Percentage
Gender	Female	32	60
	Male	21	40
	Total no. of patients	53	100
Ethnicity	Black	3	5.5
	Hispanic	39	73.5
	White	11	21
	Total no. of patients	53	100
Eye	Left	28	47
	Right	32	53
	Total no. of eyes	60	100
Glaucoma	Mild	23	38
Stage	Moderate	10	17
	Severe	23	38
	Missing	4	7
	Total no. of eyes	60	100
		Mean ± SD	Median [min–max]
Age		73.6 ± 9	74 [52–91]

Figure 1 IOP reduction in iTrack+phaco and iTrack-alone groups. Mean IOP per group (and SD) at baseline and 12- and 24-month visits is represented with a histogram. The mean IOP value for each group per time-point is depicted at the top of each bar on the graph. In each group, the mean IOP at 12 and 24 months was compared to baseline and * denotes statistically different values (*P<0.001).

Figure 2 Mean number of medications at baseline, 12 months and 24 months, across the entire cohort, in iTrack+phaco and iTrack-alone groups. The mean number of glaucoma medications used per eye (and SD) is represented with a histogram. The mean value per group at each time point is shown at the top of each bar. In each group, there is a statistically significant decrease in number of medications used at 12 and 24 months when compared to baseline (*P<0.001).

Figure 3 Stability and effectiveness of IOP reduction at 24 months postoperative in the iTrack +phaco and iTrack-alone groups. The distribution of the extent of IOP reduction from baseline (%) is represented in this figure (n=29 eyes an n=31 eyes in iTrack+phaco and iTrack-alone groups, respectively).

Figure 4 Proportion of eyes per number of medications. The proportion of eyes (%) per number of medications in each group (iTrack+phaco n=29 and iTrack-alone n=31) at baseline, 12 months and 24 months is depicted.

Table 2 Reduction in IOP and Number of Medications According to Glaucoma Severity

	Disease Severity
	Mild/Moderate			Severe
	Pre Op	12M	24M	Pre Op	12M	24M
Mean IOP in mmHg ± SD	20.8 ± 5.3	13.6±1.8	13.5±2.5	20.7±4.4	13.7±2.1	13.3±2.8
Number of eyes with IOP ≤15 mmHg		29 (87.9%)	26 (78.8%)		18 (78.3%)	18 (78.3%)
Mean number of Medications ±SD	2.6±1.1	0.9±1.1	1.4±1.3	2.9±0.7	1.3±1.1	2.1±1.2
Total number of eyes	33	33	33	23	23	23

Table 3 Corrected Visual Acuity at Baseline and at the Follow-Up Visits

	Visual Acuity: Number of Eyes per Group (%)
	All eyes			iTrack+phaco			iTrack-alone
	Pre Op	12M	24M	Pre Op	12M	24M	Pre Op	12M	24M
20/20 or better	3 (5.0)	3 (5.6)	3 (6.5)	0 (0.0)	2 (8.0)	2 (7.7)	3 (9.7)	1 (3.5)	1 (5.0)
20/40 or better	27 (45.0)	38 (70.4)	32 (69.6)	10 (34.5)	19 (76.0)	19 (73.1)	17 (54.8)	19 (65.5)	13 (65.0)
20/60 or better	43 (71.7)	45 (83.3)	41 (89.1)	19 (65.5)	21 (84.0)	24 (92.3)	24 (77.4)	24 (82.8)	17 (85.0)
20/100 or better	52 (86.7)	48 (88.9)	43 (93.5)	24 (82.8)	23 (92.0)	25 (96.2)	28 (90.3)	25 (86.2)	18 (90.0)
Tot eyes	60	54	46	29	25	26	31	29	20

Figure 5 Visual acuity. For each group, corrected distance visual acuity is represented as loss or gain of lines of Snellen at the 12- and 24-month follow-up visits, compared to baseline. Visual acuity data at 12 months were available for n=25 eyes in the iTrack+phaco group and n=29 in the iTrack-alone group. At 24 months, values were available for n=26 eyes in the iTrack+phaco group and n=20 in the iTrack-alone group.